Clinical Trial and Approval Failure Risk: The development of new pharmaceutical products involves significant uncertainty, and Eton's drug candidates may fail to demonstrate efficacy or safety in clinical trials, or may not receive necessary regulatory approvals from agencies like the FDA.

Intense Market Competition Risk: Eton operates in a highly competitive pharmaceutical market, facing established companies and new entrants developing similar therapies, which could erode market share or necessitate price reductions.

Intellectual Property Loss Risk: Eton's success depends on maintaining robust intellectual property protection for its products; however, patents may be challenged, invalidated, or expire, allowing competitors to introduce generic or biosimilar versions.